Benzamide, 5-((1,5-bis(4-methoxyphenyl)-1H-pyrazol-3-yl)dimethoxymethyl)-2-chloro- | 179325-62-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: Benzamide, 5-((1,5-bis(4-methoxyphenyl)-1H-pyrazol-3-yl)dimethoxymethyl)-2-chloro-
• 英文别名: 5-[[1,5-bis(4-methoxyphenyl)pyrazol-3-yl]-dimethoxymethyl]-2-chlorobenzamide
• CAS: 179325-62-3
• 化学式: C₂₇H₂₆ClN₃O₅
• 分子量: 508.0
• InChiKey: USJVSASRKOHVHQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  36
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  97.8
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• [EN] PYRAZOLE DERIVATIVES EXHIBITING ANTI-INFLAMMATORY AND ANALGESIC EFFECTS<br/>[FR] DERIVES PYRAZOLE PRESENTANT DES EFFETS ANTI-INFLAMMATOIRES ET ANALGESIQUES
  申请人：EISAI CO., LTD.

  公开号：WO1996014302A1

  公开（公告）日：1996-05-17

  (EN) Pyrazole derivatives represented by formula (I) and physiologically acceptable salts thereof can suppress the production of both of prostaglandins and leukotrienes simultaneously, and, therefore, exhibit anti-inflammatory and analgesic effects.(FR) Des dérivés pyrazole représentés par la formule (I) et leurs sels physiologiquement tolérables peuvent supprimer simultanément la production des prostaglandines et des leucotriènes, et, par conséquent, présentent des effets anti-inflammatoires et analgésiques.

  (中) 由公式（I）表示的吡唑衍生物及其生理上可接受的盐可以同时抑制前列腺素和白三烯的产生，因此具有抗炎和镇痛作用。
• JPH09208459A
  申请人：——

  公开号：JPH09208459A

  公开（公告）日：1997-08-12
• Use of Ltb4 Inhibitors for the Treatment of B-Cell Leukemias and Lymphomas
  申请人：Claesson Hans-Erik

  公开号：US20080081835A1

  公开（公告）日：2008-04-03

  The invention relates to the use of an inhibitor of the biosynthesis and/or function of LTB 4 for the manufacture of a medicament for the treatment of B-cell chronic lymphocytic leukemia (B-CLL), B-prolymphocytic leukemia (B-PLL) or B-cell lymphoma. Preferably, the inhibitor of the biosynthesis and/or function of LTB 4 is the inhibitor of 5-LO BWA4C or the inhibitor of FLAP MK-886.
• Method and composition for treating inflammatory disorders
  申请人：Pereswetoff-Morath Lena

  公开号：US20090220583A1

  公开（公告）日：2009-09-03

  There is provided homogeneous pharmaceutical compositions for the treatment of inflammatory disorders comprising an antiinflammatory and/or antihistaminic active ingredient, a polar lipid liposome and a pharmaceutically-acceptable aqueous carrier.
• NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS
  申请人：Chen Chien-Hung

  公开号：US20120183600A1

  公开（公告）日：2012-07-19

  The invention relates to a composition that includes a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5′-monophosphate-activated protein kinase (AMPK) activator; a second agent that possesses anti-inflammatory activity; and a third agent that possesses serotonin activity.